Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 43Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Mantle-Cell 3Lymphoma 3Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Genetic Diseases, Inborn 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Dexamethasone 11Lenalidomide 9Calcium Dobesilate 5carfilzomib 4daratumumab 3isatuximab 2iberdomide 2elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Leflunomide 2Denosumab 2selinexor 1pomalidomide 1piperine 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1Simvastatin 1Nivolumab 1Metformin 1Melphalan 1IPH-2101 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Cyclophosphamide 1Curcumin 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Smoldering Multiple Myeloma × ixazomib × Clear all
NCT02916771 2025-08-11

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
61 enrolled 12 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡